EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Optimizing Lipid Nanoparticles for Delivery in Primates

Kieu Lam iD, Petra Schreiner, Ada Leung, Paul Stainton, Steve Reid, Ed Yaworski, Pete Lutwyche, James Heyes iD

Advanced Materials · 2023-06 · 35 (26)

DOI: 10.1002/adma.202211420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 11.05.2023. Verfasst von Kieu Lam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genevant Sciences Corporation, Vancouver, BC, V5T 4T5, Canada. Hauptthemen laut MEDLINE: Lipids, Nanoparticles. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles (LNPs) are clinically proven to successfully deliver both small interfering RNA (siRNA) therapeutics and larger mRNA payloads for prophylactic vaccine applications. Non‐human primates (NHPs) are generally considered to be the most predictive of human responses. However, for ethical and economic reasons, LNP compositions have historically been optimized in rodents. It has been difficult to translate LNP potency data from rodents to NHPs for intravenously (IV) administered products in particular. This presents a major challenge for preclinical drug development. An attempt to investigate LNP parameters, which have historically been optimized in rodents, is carried out, and seemingly innocuous changes are found to result in large potency differences between species. For example, the ideal particle size for NHPs (50–60 nm) is found to be smaller than for rodents (70–80 nm). Surface chemistry requirements are also different, with almost double the amount of poly(ethylene glycol) (PEG)‐conjugated lipid needed for maximal potency in NHPs. By optimizing these two parameters, approximately eight‐fold increase in protein expression from intravenously administered messenger RNA (mRNA)‐LNP in NHP is gained. The optimized formulations are well tolerated when administered repeatedly with no loss of potency. This advancement enables the design of optimal LNP products for clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidsNanoparticlesAnimalsLiposomesRNA, Small InterferingPrimatesRNA, Messenger

Stichwörter der Autor:innen

PEG shieldinglipid nanoparticlesnanotechnologynucleic acidparticle sizepotency translationtherapeutics

Substanzen

Lipid NanoparticlesLipidsLiposomesRNA, Small InterferingRNA, Messenger

Autor:innen und Institutionen

  • Genevant Sciences Corporation, Vancouver, BC, V5T 4T5, Canada.

ORCID-Profile: Kieu Lam, James Heyes

Zitieren

APA

Lam, K., Schreiner, P., Leung, A., Stainton, P., Reid, S., Yaworski, E., Lutwyche, P., & Heyes, J. (2023). Optimizing Lipid Nanoparticles for Delivery in Primates. Advanced Materials, 35(26). https://doi.org/10.1002/adma.202211420

Vancouver

Lam K, Schreiner P, Leung A, Stainton P, Reid S, Yaworski E, et al. Optimizing Lipid Nanoparticles for Delivery in Primates. Advanced Materials. 2023;35(26). doi:10.1002/adma.202211420

BibTeX
@article{Lam2023,
  author = {Lam, Kieu and Schreiner, Petra and Leung, Ada and Stainton, Paul and Reid, Steve and Yaworski, Ed and Lutwyche, Pete and Heyes, James},
  title = {Optimizing Lipid Nanoparticles for Delivery in Primates},
  journal = {Advanced Materials},
  year = {2023},
  volume = {35},
  number = {26},
  doi = {10.1002/adma.202211420}
}
Kostenlos starten →